- Home
- GLAD vs RIGL Comparison
GLAD vs RIGL Comparison
Compare GLAD & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLAD | RIGL |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.1M | 537.6M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | GLAD | RIGL |
|---|---|---|
| Price | $21.41 | $48.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $22.33 | ★ $43.20 |
| AVG Volume (30 Days) | 206.8K | ★ 650.0K |
| Earning Date | 11-17-2025 | 11-04-2025 |
| Dividend Yield | ★ 9.35% | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | 2.55 | ★ 6.20 |
| Revenue | $89,122,000.00 | ★ $282,076,000.00 |
| Revenue This Year | $16.57 | $65.53 |
| Revenue Next Year | $4.98 | $0.22 |
| P/E Ratio | $8.32 | ★ $7.60 |
| Revenue Growth | N/A | ★ 79.13 |
| 52 Week Low | $18.76 | $14.63 |
| 52 Week High | $30.43 | $52.24 |
Technical Indicators
Market Signals| Indicator | GLAD | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 65.31 | 63.11 |
| Support Level | $20.70 | $43.81 |
| Resistance Level | $21.35 | $52.24 |
| Average True Range (ATR) | 0.44 | 3.28 |
| MACD | 0.17 | -0.19 |
| Stochastic Oscillator | 97.89 | 67.79 |
Price Performance
Historical ComparisonAbout GLAD Gladstone Capital Corporation
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.